Report Sections

See All Reports

Coronavirus Infections (819) Severe Acute Respiratory Syndrome (567) Infection (472) Pneumonia (366) Communicable Diseases (199) Respiratory Distress Syndrome, Adult (179) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) Respiratory Insufficiency (132) Syndrome (105) Virus Diseases (90) Pneumonia, Viral (82) Depression (67) Critical Illness (62) Anxiety Disorders (41) Cardiovascular Diseases (36) Emergencies (36) Respiratory Tract Infections (36) Stress, Psychological (31) Hypoxia (30) Inflammation (30) Lung Injury (30) Neoplasms (30) Wounds and Injuries (30) Stress Disorders, Post-Traumatic (29) Thrombosis (28) Diabetes Mellitus (26) Disease (26) Respiratory Tract Diseases (26) Depressive Disorder (25) Stress Disorders, Traumatic (25) Lung Diseases (23) Acute Kidney Injury (22) Disease Progression (22) Mental Disorders (21) Olfaction Disorders (20) Respiration Disorders (20) Burnout, Psychological (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Dyspnea (12) Fibrosis (12) Influenza, Human (12) Arthritis, Rheumatoid (11) Rheumatic Diseases (11) Venous Thrombosis (11) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Heart Failure (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Infarction (8) Liver Diseases (8) Lung Diseases, Obstructive (8) Multiple Sclerosis (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Autoimmune Diseases (7) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lymphopenia (7) Pulmonary Disease, Chronic Obstructive (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Adenoviridae Infections (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Nervous System Diseases (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Colorectal Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Fibromyalgia (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Sleep Initiation and Maintenance Disorders (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Ageusia (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bipolar Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypersensitivity (3) Hypertension, Pulmonary (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) Muscle Weakness (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Myofascial Pain Syndromes (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Atrophy (2) Bacteremia (2) Behcet Syndrome (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Cerebral Palsy (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Common Cold (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) Constriction, Pathologic (2) Coronavi (2) Dementia (2) Depressive Disorder, Major (2) Developmental Disabilities (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Esophageal Neoplasms (2) Eye Diseases (2) Fever (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Ischemia (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Muscular Atrophy (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) Osteoporosis (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) Scleroderma, Diffuse (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Skin Diseases (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Agoraphobia (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) Com (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Conversion Disorder (1) Coron (1) Coronavirus Infect (1) Cr (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) DiGeorge Syndrome (1) Diabetes Complications (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Emergen (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gastrointestinal Neoplasms (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyp (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) Inf (1) Infant, Newborn, Diseases (1) Infe (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intestinal Neoplasms (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Dystrophies (1) Musculoskeletal Diseases (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neurodegenerative Diseases (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pn (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Renal Insufficie (1) Reperfusion Injury (1) Resp (1) Respi (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) Se (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Tracheal Stenosis (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D003095: Collagen Diseases

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (22)


Name (Synonyms) Correlation
drug869 Control Wiki 0.42
drug1066 Disease-modifying antirheumatic drugs (DMARDs) Wiki 0.33
drug1579 IER-R (posttraumatic stress) Wiki 0.33
Name (Synonyms) Correlation
drug562 CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki 0.33
drug4008 placebo rinse Wiki 0.33
drug640 COVID-19 test Wiki 0.33
drug2754 RAPID-3 Wiki 0.33
drug1634 Immunosuppressive Agents Wiki 0.33
drug631 COVID-19 infection Wiki 0.33
drug3649 WHOQOL-BREF Wiki 0.33
drug968 DASS-21 instrument (depression and anxiety) Wiki 0.33
drug870 Control (albumin 5%) Wiki 0.33
drug511 Breath Biopsy Wiki 0.33
drug3101 Simulation Intervention Wiki 0.33
drug3533 Ultra Brief Online Mindfulness-based Intervention Wiki 0.33
drug4039 questionnaire assesment Wiki 0.30
drug1930 MSC Wiki 0.24
drug638 COVID-19 survey Wiki 0.24
drug491 Blood sampling Wiki 0.24
drug886 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.24
drug3628 Vitamin C Wiki 0.09
drug2730 Questionnaire Wiki 0.06

Correlated MeSH Terms (18)


Name (Synonyms) Correlation
D012216 Rheumatic Diseases NIH 0.90
D012213 Rheumatic Fever NIH 0.38
D013166 Spondylitis NIH 0.33
Name (Synonyms) Correlation
D013167 Spondylitis, Ankylosing NIH 0.33
D015535 Arthritis, Psoriatic NIH 0.33
D001168 Arthritis NIH 0.26
D001167 Arteritis NIH 0.24
D001172 Arthritis, Rheumatoid NIH 0.20
D025241 Spondylarthritis NIH 0.19
D011111 Polymyalgia Rheumatica NIH 0.19
D013700 Giant Cell Arteritis NIH 0.19
D008180 Lupus Erythematosus, Systemic NIH 0.14
D001327 Autoimmune Diseases NIH 0.13
D059350 Chronic Pain NIH 0.11
D003141 Communicable Diseases NIH 0.02
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0001369 Arthritis HPO 0.27
HP:0012089 Arteritis HPO 0.24
HP:0001370 Rheumatoid arthritis HPO 0.21
Name (Synonyms) Correlation
HP:0002960 Autoimmunity HPO 0.15
HP:0002725 Systemic lupus erythematosus HPO 0.14
HP:0012532 Chronic pain HPO 0.11

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials


1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747
Conditions
  1. Rheumatoid Arthritis
  2. Psoriatic Arthritis
  3. Axial Spondyloarthritis
  4. Systemic Lupus Erythematosus
  5. Giant Cell Arteritis
Interventions
  1. Other: COVID-19 infection
MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

Measure: Disease activity

Time: Last registration of disease activity in the medical journal before admission/inclusion

Secondary Outcomes

Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

Measure: Immune modulating treatments

Time: Current immune modulating treatments at admission/inclusion

Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

Measure: Biomarkers

Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

NCT04351399
Conditions
  1. Sars-CoV2
  2. Rheumatic Diseases
  3. Rheumatoid Arthritis
  4. Chronic Pain
Interventions
  1. Other: questionnaire assesment
MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Measure: Frequency of RA patients with emotional impact (feeling of isolation)

Time: maximum 1 week from baseline on

Secondary Outcomes

Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

Measure: self-reported questionnaire for painful

Time: maximum 1 week from baseline on
3 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT04353609
Conditions
  1. Sars-CoV2
  2. Chronic Inflammatory Rheumatism
  3. Autoimmune Diseases
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity

Primary Outcomes

Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

Time: From Baseline up to Day 21 after first symptoms of covid-19

Secondary Outcomes

Measure: Proportion of patients who die from a severe form of covid-19

Time: From Baseline up to Day 21 after first symptoms of covid-19

Measure: Proportion of patients who present an history of diabetes according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)

Time: At the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Asthma according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Hypertension according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cardiac disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of stroke according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cancer according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
4 Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants

A retrospective monocentric study with large active files of patients monitored for rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus with as main endpoint the morbimortality of Covid-19 in these patients (number of patients hospitalized in conventional units and/or in intensive care and/or deceased). The results will be compared with those of the general population based on the epidemiological data of Covid-19.

NCT04426279
Conditions
  1. Sars-CoV2
  2. Rheumatoid Arthritis
  3. Rheumatic Diseases
Interventions
  1. Other: questionnaire assesment
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS. The diagnosis of Covid-19 is either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. The results will be compared with those of the general population based on Covid-19 epidemiological data.

Measure: analysis of Covid-19-related morbidity and mortality in patients with IRC under IS.

Time: At 6 months

Secondary Outcomes

Description: Diagnosis of Covid-19 either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology.

Measure: To evaluate the frequency of Covid-19 in patients with IRC under IS.

Time: At 6 months

Description: The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave (March to August 2020) and the six-month period preceding it (September to February 2020).

Measure: To compare the morbidity and mortality of patients with IRC under IS during the Covid-19 epidemic wave (March to August 2020) with the six months prior to this wave (September 2019 to February 2020).

Time: At 6 months

Description: The number of patients who maintained, modified, or discontinued their treatment. Treatment modification will be assessed by the number of weeks of treatment not taken, the number of injections not given, the number of delayed or missed infusions. Among those who have modified or stopped their treatment, the impact on their diseases will be evaluated by the loss of remission, the patient's opinion on the notion of relapse, the increase or initiation of corticosteroid therapy and the substantive change in treatment.

Measure: Patients' conduct in relation to their treatment during the epidemic wave (maintenance, modification or discontinuation) and the impact on their disease (loss of remission, flare, corticosteroids requirement and need for switch of DMARD therapy)

Time: At 6 months
5 COVID-19 Prevalence in a Single Large UK Rheumatology Centre and the Impact on Quality of Life From Stringent Social Distancing

The COVID-19 pandemic represents a threat to rheumatology patients. National advice for patients to 'shield' is based on risk stratification of therapies and other risk factors. While the epidemiology of COVID-19 in the rheumatological population is largely unknown large case registries are beginning to show potential drug treatment interactions. Strict self-isolation (shielding) has been recommended for those deemed 'high risk' although its impact on the likelihood of COVID-19 infection and health related quality of life (HRQoL) is unclear. The study aims to explore how this unprecedented situation has impacted the Trust patients primarily evaluating prevalence of the infection, effect of stringent social distancing (shielding) and Quality of Life (QOL). This will be done via a voluntary questionnaire, sent via text messaging at 6 and 12 months.

NCT04542031
Conditions
  1. Covid19
  2. Rheumatic Diseases
Interventions
  1. Other: Questionnaire
MeSH:Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: percentage of cases

Measure: Prevalence of COVID 19

Time: 1 year

Description: number of deaths per 1000 individuals

Measure: Mortality rates from COVID 19

Time: 1 year

Description: mental and physical component scores through patient reported outcomes. Normative score set at 50 with minimum score being 0 and maximum score being 100. Scores >50 indicate better mental or physical health than the mean. Scores <50 indicate worse mental or physical health than the mean

Measure: Health related quality of life - Short Form 12

Time: 1 year
6 Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in México During the COVID-19 Pandemic

The National Institute of Medical Sciences and Nutrition is a national reference center for rheumatic diseases that belongs to The National Institutes of Health, and has Federal founding. More than 8,000 patients with a wide variety of rheumatologic diagnosis receive medical care. On March 2020, the WHO announced COVID-19 outbreak a pandemic. The first case was registered in Mexico on February 2020. In March 2020, the Mexican Government requested that our Institution should restrict health care to exclusively COVID-19 patients; accordingly, outpatient consultations were, and up to August 2020 still, hold on. Meanwhile, when possible, the Department of Immunology and Rheumatology has implemented an "on-demand", non-organized patient´s health care, through email and phone contact; nonetheless, and due to the middle-low socioeconomic status of most of our patients and limited technical resources available at our Institution, the attempt has been challenging.

NCT04557358
Conditions
  1. Rheumatoid Arthritis
  2. Quality of Life
Interventions
  1. Other: COVID-19 survey
  2. Other: RAPID-3
  3. Other: WHOQOL-BREF
  4. Other: DASS-21 instrument (depression and anxiety)
  5. Other: IER-R (posttraumatic stress)
MeSH:Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: To determinate the proportion of the rheumatic disease patients affected in their usual medical care during the COVID-19 pandemic in our Institution with the COVID-19 survey (locally development)

Measure: Change in the pattern of the usual medical care among the rheumatic disease patients

Time: At study inclusion (The first medical consultation posterior to open the external outpatient's service, post COVID-19 pandemic)

Secondary Outcomes

Description: Change in the activity disease measured as RAPID-3 of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 30 a > number > disease activity

Measure: Change in the patient's activity disease

Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up

Description: Change in the activity disease measured by their rheumatologist (4 questions) of the rheumatic disease patients in a 6 months follow-up. The results will express with 3 categories (without activity, low activity, moderate activity, high activity)

Measure: Change in the patient's activity disease measures by their rheumatologist

Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up

Description: Change in the quality of life measured as WHOQOL-BREF of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 100 a > number > quality of life

Measure: Change in patient´s quality of life

Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up

Description: Change in the psychopathology measured as DASS-21 instrument (depression and anxiety) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 8 a cut of point > 8 suggests depression and stress presence, and > 5 suggests anxiety presence

Measure: Change in patient´s depression and anxiety

Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up

Description: Change in the psychopathology measured as IER-R (posttraumatic stress) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 88 a cut of point > 24 would be significant

Measure: Change in patient´s posttraumatic stress

Time: In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up
7 Predictive Factors for COVID-19 in Rheumatology Study Based on Information Collected in The COVID-19 Global Rheumatology Alliance

We seek to study the behaviour of Coronavirus infection in patients with rheumatological and/or autoimmune comorbidities, understood as a particular pathophysiological universe with its own risks and eventual benefits, until now fully hypothetical to be confirmed by means of real and recent evidence. On March 12, 2020, an initiative called the Global Alliance for COVID-19 in Rheumatology (The COVID-19 Rheumatology Alliance) arises, as a rapid response of international coordination whose ultimate goal is to serve as help or guideline for all those doctors who seek be faced with receiving, evaluating, understanding and caring for a patient with rheumatological and / or autoimmune diseases in relation to the imminent risk of COVID-19.

NCT04567576
Conditions
  1. Rheumatic Diseases
  2. Covid19
Interventions
  1. Drug: Disease-modifying antirheumatic drugs (DMARDs)
MeSH:Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: It will be considered as 1. Severe, if it meets at least one of the following characteristics (based on what is registered in the main center's database): If you were hospitalized: What was the highest level of care you required during the illness? → o Required invasive mechanical ventilation or extracorporeal membrane oxygenation If the symptoms did not resolve and the patient was hospitalized: What is the highest level of care that has been required in the course of the present illness so far? o Required mechanical ventilation or extracorporeal membrane oxygenation

Measure: Clinical behavior of the disease // COVID-19

Time: 1-12 weeks

Description: It will be considered as 1. Yes, if it meets at least one of the following characteristics (based on what is registered in the main center's database): • Has the patient died? o Yes, he passed away

Measure: Mortality

Time: 1-12 weeks
8 Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection

SAR-COVID is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and SARS-CoV-2 infection (asymptomatic or COVID-19). Hypothesis: Patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder COVID-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments.

NCT04568421
Conditions
  1. Rheumatic Diseases
Interventions
  1. Drug: Immunosuppressive Agents
MeSH:Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: Death caused by SARS-CoV-2 infection

Measure: Mortality

Time: 2 month

Description: Hospitalization because of SARS-CoV-2 infection

Measure: Hospitalization

Time: 2 month

Secondary Outcomes

Description: To describe clinical presentation of SARS-CoV-2 infection in patients with rheumatic diseases

Measure: SARS-CoV-2 infection presentation

Time: 1 month

Description: Proportion of patients admitted at the intensive care unit

Measure: Admission at the intensive care unit

Time: 2 month

Description: Proportion of patients who required invasive mechanical ventilation

Measure: Invasive mechanical ventilation

Time: 2 month

Description: Proportion of patients who had complications associated with COVID-19 infection and describe them

Measure: COVID-19 Complications

Time: 2 month

Description: Proportion of patients fully or partially recovered after COVID-19 infection.

Measure: Recovery rate

Time: 2 month
9 Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

NCT04655612
Conditions
  1. COVID-19
  2. SARS-CoV Infection
  3. Rheumatoid Arthritis
  4. Spondyloarthritis
  5. Ankylosing Spondylitis
  6. Psoriatic Arthritis
MeSH:Infection Communicable Diseases Spondylitis Coronavirus Infections Severe Acute Respiratory Syndrome Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Spondylitis, Ankylosing Rheumatic Diseases Spondylarthritis Collagen Diseases
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

Time: 1 day

Secondary Outcomes

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

Time: 1 day

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

Time: 1 day

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

Time: 1 day

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on January 01, 2021.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook